摘要
目的观察希罗达单药治疗晚期结直肠癌的临床疗效,探讨影响近期疗效的相关因素。方法 78例晚期结直肠癌患者予以口服希罗达每日2500mg/m 2,分早晚各1次,餐后服用,连续服用14天后停药7天。治疗周期为21天,至少治疗2个周期。观察患者近期疗效,采用Logistic回归分析影响疗效的因素。结果本组完全缓解(complete response,CR)5例,部分缓解(partial response,PR)20例,病情稳定(stable disease,SD)31例,病情进展(progress disease,PD)22例,总有效率32.05%。Logistic回归分析显示希罗达治疗无效的独立危险因素有年龄(OR=1.52,95%CI 1.01 5~2.319)、空腹血糖(OR=1.30,95%CI 1.483~3.677)、白蛋白(OR=1.98,95%CI 1.526~2.572)、丙氨酸氨基转移酶(OR=2.37,95%CI 1.621~3.509)、门冬氨酸氨基转移酶(OR=2.21,95%CI 1.526~2.572)。结论希罗达单药治疗晚期结直肠癌疗效确切,但治疗无效率也较高,与多种因素有关,应对患者病情进行综合评估,采用有效的治疗方法,以提高近期临床疗效。
Objective To explore the clinical effects of single-agent Xeloda (Capecitabine) therapy and the related risk factors in patients with advanced colorectal cancer. Method Seventy-eight patients with advanced colorectal cancer were treated with oral Xeloda, 1250 mg/m 2 twice daily, on days 1-14 every 21 days. At least 2 cycles were administered. The short-term clinical effects were evaluated, and the related risk factors were tested by Logistic regression analysis. Results The overall response rate was 32.05%with 5 cases complete response (CR), 20 cases partial response (PR), 31 cases stable disease (SD), 22 cases progress disease (PD). The Logistic regression analysis showed that the age (OR=1.52, 95%CI 1.015~2.319), fast blood glucose (OR=1.30, 95%CI 1.483~3.677), albumin (OR=1.98, 95%CI 1.526~2.572), ALT (OR=2.37, 95%CI 1.621~3.509) and AST (OR=2.21, 95%CI 1.526~2.572) were independent risk factors for inefficient treatment. Conclusion The single-agent Xeloda (Capecitabine) is an efficacious treatment for the patients with advanced colorectal cancer. However, the inefficient rate is also high and it relates to a variety of factors. We should comprehensively evaluate the patients to improve the short-term clinical effects.
出处
《中国生化药物杂志》
CAS
北大核心
2014年第1期111-112,115,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
希罗达
晚期结直肠癌
临床疗效
Xeloda(Capecitabine)
advanced colorectal cancer
clinical effects
